Welcome to our dedicated page for Iperionx SEC filings (Ticker: IPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IperionX Limited (IPX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. IperionX files annual reports on Form 20-F and furnishes current information on Form 6-K, including quarterly reports, sustainability reports, notices of annual general meeting, trading halt requests and press releases related to its titanium and critical minerals operations.
Through these filings, investors can review how IperionX describes its business as an American titanium metal and critical materials company that uses patented technologies to produce high performance titanium alloys from titanium minerals or scrap titanium. Annual and quarterly reports furnished as exhibits to Form 6-K outline the status of the Titanium Manufacturing Campus in Virginia, the Titan Critical Minerals Project in Tennessee, government funding arrangements, customer programs and risk factors associated with scaling titanium production and commercialization.
Filings also document U.S. Government support, including Defense Production Act Title III investments, Industrial Base Analysis and Sustainment awards, and the Small Business Innovation Research (SBIR) Phase III Indefinite Delivery, Indefinite Quantity contract that enables task orders for titanium components. These documents provide detail on how such programs are structured and how they relate to IperionX’s plans to expand titanium capacity and develop a mineral-to-metal supply chain.
On Stock Titan, users can view these SEC submissions as they are furnished to EDGAR and use AI-powered summaries to interpret complex sections. The platform highlights key elements of IperionX’s 20-F and 6-K exhibits, helping readers quickly understand disclosures about production capacity, government contracts, critical minerals resources, financial reporting practices and other material information contained in the company’s official filings.
IPERIONX Ltd Chief Financial Officer Marcela Rocha Castro received new equity awards. She was granted options over 127,993 IPX Ordinary Shares at an exercise price of A$11 per share and 52,258 restricted stock units, both dated April 2, 2026.
Each option allows the purchase of one ordinary share at the stated conversion price. Following these awards, she directly holds 340,795 ordinary shares and 214,259 restricted stock units. Existing options with a conversion price of A$5 over IPX Ordinary Shares remain outstanding, and the restricted stock units vest on a schedule extending to April 2029.
IPERIONX Ltd President Toby Edgcumbe Symonds reported new equity awards and updated holdings. He received 226,047 performance rights tied to an A$18 share price hurdle and service conditions, plus 536,521 options at A$18 and 607,244 options at A$22, each over IPX ordinary shares. These are compensation-related grants, not market purchases or sales. After these awards, he reports direct ownership of 3,188,146 ordinary shares, 110,000 American Depositary Shares, and substantial additional performance rights and restricted stock units that may convert into ordinary shares if their conditions are met.
Arima Anastasios reported acquisition or exercise transactions in this Form 4 filing.
IPERIONX Ltd Chief Executive Officer Anastasios Arima received multiple new equity awards. On 2026-04-02, he was granted 237,944 performance rights tied to an A$18.00 stock-price hurdle and four years of continuous service, each convertible into one ordinary share once the performance criteria are met.
He was also granted options over 564,759 IPX ordinary shares at A$18.00 and 639,205 shares at A$22.00, each exercisable from 2030-04-02 and expiring on 2031-04-02. These are compensation-related awards, not open-market share purchases or sales.
Following these grants, Arima holds 12,206,782 ordinary shares directly, 128,000 American Depository Shares listed on Nasdaq (each equal to ten ordinary shares), 435,806 performance rights at each of A$6.00, A$7.00 and A$8.00, and 738,576 restricted stock units.
IPERIONX Ltd Executive Chairman Todd Hannigan received new equity awards in the form of performance rights and options linked to IPX Ordinary Shares. On April 2, 2026, he was granted 196,086 performance rights and 465,410 options each with an exercise price of A$18.00, plus 526,760 options with an exercise price of A$22.00.
Each performance right can convert into one ordinary share if service and stock price performance conditions are met, and each option allows purchase of one ordinary share at the stated price. Following these awards, he holds 25,628,334 Ordinary Shares directly, alongside existing derivative positions and 500,000 ADS representing IPX Ordinary Shares.
IPERIONX Ltd President Toby Edgcumbe Symonds made an open‑market purchase of 11,000 American Depository Shares (ADS) of IPERIONX at an average price of $23.8684 per ADS. Each ADS represents 10 ordinary shares traded on the Australian Stock Exchange.
After this transaction, he directly holds 11,000 ADS, 3,188,146 ordinary shares, and 703,199 Restricted Stock Units. He also holds performance rights over ordinary shares with exercise prices of A$4, A$6, A$7 and A$8, exercisable or expiring between December 2028 and April 2030.
IPERIONX Ltd director R. Tony Tripeny bought shares on the open market. He purchased 4,187 American Depository Shares at an average price of $23.7554 per ADS in an open‑market transaction. Following this purchase, he directly holds 4,187 ADS, 38,777 ordinary shares, and 51,010 restricted stock units. One ADS is convertible into 10 ordinary shares, and the RSUs are scheduled to vest in tranches of 36,848 in December 2026 and 14,162 in December 2027.
IPERIONX Ltd director Hannigan Todd made an open-market purchase of 225,225 Ordinary Shares at $3.2009 per share. After this transaction, he directly holds 25,628,334 Ordinary Shares.
He also holds performance rights over 306,302 underlying Ordinary Shares at each of A$6, A$7 and A$8 exercise prices, plus 454,464 Restricted Stock Units and 50,000 American Depository Shares, where each ADS is convertible into 10 Ordinary Shares.
IPERIONX Ltd Chief Executive Officer Arima Anastasios reported significant open-market share purchases. On March 27, 2026, he bought 467,000 Ordinary Shares at an average price of A$3.198, taking his direct Ordinary Share holdings to 12,206,782.
On the same date, he also bought 12,800 American Depository Shares (ADS) at an average price of $23.4097, and now holds 12,800 ADS directly. Each ADS represents 10 Ordinary Shares.
He also holds Performance Rights over 435,806 underlying Ordinary Shares at each of A$6, A$7, and A$8, all expiring on April 10, 2030, plus 738,576 Restricted Stock Units, with 318,666 vesting in December 2026 and 419,910 in April 2028.
IPERIONX Ltd President Toby Symonds has filed an initial ownership report detailing his equity and incentive holdings. He directly holds 3,128,089 Ordinary Shares traded on the ASX and 23,000 American Depository Shares listed on NASDAQ, with each ADS representing 10 ordinary shares.
He also holds 703,199 Restricted Stock Units, with 302,666 vesting in December 2026 and 400,533 vesting in April 2028. In addition, he has Performance Rights over 1,110,000 underlying Ordinary Shares at A$4 expiring on December 21, 2028, and 415,695 underlying shares at each of A$6, A$7, and A$8 exercise prices, all expiring on April 10, 2029.
IPERIONX Ltd director Hannigan Todd has filed an initial Form 3 reporting his existing equity interests in the company. The filing lists direct ownership of 25,403,109 Ordinary Shares, 454,464 Restricted Stock Units, and 50,000 American Depository Shares, each ADS representing ten Ordinary Shares traded on NASDAQ.
He also holds performance rights over 306,302 underlying IPX Ordinary Shares at each of A$6, A$7, and A$8 exercise prices, expiring in April 2030. Footnotes state that 159,334 units vest in December 2026 and 295,130 vest in April 2028, highlighting a structured, long-term incentive position rather than new market transactions.